New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:53 EDTMNKDPanel raised questions about Afrezza's commercial outlook, says Piper Jaffray
Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
06:02 EDTMNKDMannKind implied volatility of 56 at lower end of index mean range
Subscribe for More Information
September 9, 2014
06:04 EDTMNKDMannKind implied volatility of 56 at lower end of index mean range

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use